Want to see ELTX full AI Analyst Report?
ELTX Stock Chart & Stats
$13.55
$0.10(1.66%)
At close: 4:00 PM EST
$13.55
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$2.66 - $16.00
Previous CloseN/A
Volume37.28K
Average Volume (3M)2.98M
Market Cap
$81.90M
Enterprise Value$89.29M
Total Cash (Recent Filing)$14.95M
Total Debt (Recent Filing)$14.34M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 07, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding23,466,394
10 Day Avg. Volume1,443,350
30 Day Avg. Volume2,984,744
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-308.95
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$20.67Price Target Upside52.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Clinical Activity (synergy With PD‑1)Elicio observed rare confirmed complete responses when ELI-002 7P was followed by nivolumab, with persistent mKRAS-specific T-cell responses. This biological signal suggests the platform may prime resistant tumors for checkpoint response, a durable differentiation that can enable combination strategies and faster paths to meaningful indications.
Refined Registrational Strategy (R0 Subgroup)Management’s pivot to a focused Phase 3 in R0 resected patients with extended dosing and DFS endpoint shows adaptive trial design based on Phase 2 learnings. Narrowing population improves signal-to-noise, can reduce trial size and timing risk, and represents a pragmatic path to regulatory relevance if biology holds.
New $15M Registered Direct Offering Strengthens RunwayThe $15M registered direct offering, led by new institutional investors plus an existing large holder, provides near-term capital to advance planned Phase 1 development and platform work. Fresh institutional backing improves financing optionality and materially extends near-term runway to support clinical milestones.
Bears Say
No Revenue; Persistent Heavy Cash BurnElicio remains a pre-revenue biotech with sustained multi-year operating losses and large negative free cash flow. This structural cash burn necessitates repeated external financing, constrains strategic choices, increases dilution risk, and limits capacity to independently fund larger registrational programs without partners.
Negative Stockholders' Equity; Weakened Balance SheetNegative equity reflects accumulated losses and a thin capital base, reducing financial flexibility. With limited assets and modest absolute debt, the company faces higher financing costs and greater dilution risk when raising capital, and weaker ability to absorb trial setbacks or fund longer development timelines organically.
Phase 2 Missed Primary EndpointMissing the Phase 2 primary endpoint imposes durable program risk: it necessitates amended trial design and additional data to convince regulators and payers. Even with supportive subgroup biology, this outcome increases development complexity, raises costs, and delays potential commercialization unless prospectively validated.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics, Inc’s price range in the past 12 months?
Elicio Therapeutics, Inc lowest stock price was $2.66 and its highest was $16.00 in the past 12 months.
What is Elicio Therapeutics, Inc’s market cap?
Elicio Therapeutics, Inc’s market cap is $81.90M.
When is Elicio Therapeutics, Inc’s upcoming earnings report date?
Elicio Therapeutics, Inc’s upcoming earnings report date is Aug 07, 2026 which is in 29 days.
How were Elicio Therapeutics, Inc’s earnings last quarter?
Elicio Therapeutics, Inc released its earnings results on May 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.465 by -$0.185.
Is Elicio Therapeutics, Inc overvalued?
According to Wall Street analysts Elicio Therapeutics, Inc’s price is currently Undervalued.
Does Elicio Therapeutics, Inc pay dividends?
Elicio Therapeutics, Inc does not currently pay dividends.
What is Elicio Therapeutics, Inc’s EPS estimate?
Elicio Therapeutics, Inc’s EPS estimate is -0.54.
How many shares outstanding does Elicio Therapeutics, Inc have?
Elicio Therapeutics, Inc has 23,466,394 shares outstanding.
What happened to Elicio Therapeutics, Inc’s price movement after its last earnings report?
Elicio Therapeutics, Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.465. Following the earnings report the stock price went down -9.13%.
Which hedge fund is a major shareholder of Elicio Therapeutics, Inc?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (52.52% Upside)
$20.67 (52.52% Upside)
Blogger Sentiment
Bearish
ELTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 44.2%
Last 30 Days ▲ 44.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.05%
12-Months-Change
Fundamentals
Return on Equity
-2748.16%
Trailing 12-Months
Asset Growth
-19.38%
Trailing 12-Months
Company Description
Elicio Therapeutics, Inc
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$20.67
▲(52.52% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
1.17% Insiders
3.30% Mutual Funds
4.40% Other Institutional Investors
85.82% Public Companies and
Individual Investors